Our previous studies identified the oncogenic role of
p21-activated kinase 1 (PAK1) in
hepatocellular carcinoma (HCC) and
renal cell carcinoma (RCC). Contrarily, PAK6 was found to predict a favorable prognosis in RCC patients. Nevertheless, the ambiguous
tumor suppressive function of PAK6 in hepatocarcinogenesis remains obscure. Herein, decreased PAK6 expression was found to be associated with
tumor node
metastasis stage progression and unfavorable overall survival in HCC patients. Additionally, overexpression and silence of PAK6 experiments showed that PAK6 inhibited xenografted
tumor growth in vivo, and restricted cell proliferation, colony formation, migration, and invasion and promoted cell apoptosis and anoikis in vitro. Moreover, overexpression of
kinase dead and
nuclear localization signal deletion mutants of PAK6 experiments indicated the
tumor suppressive function of PAK6 was partially dependent on its
kinase activity and nuclear translocation. Furthermore, gain or loss of function in
polycomb repressive complex 2 (PRC2) components, including EZH2, SUZ12, and EED, elucidated epigenetic control of H3K27me3-arbitrated PAK6 down-regulation in
hepatoma cells. More importantly, negative correlation between PAK6 and EZH2 expression was observed in
hepatoma tissues from HCC patients. These data identified the
tumor suppressive role and potential underlying mechanism of PAK6 in hepatocarcinogenesis.